Cargando…

Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells

Gamma delta T lymphocytes (γδT cells) have pleiotropic properties including innate cytotoxicity, which make them attractive effectors for cancer immunotherapy. Combination treatment with zoledronic acid and IL-2 can activate and expand the most common subset of blood γδT, which express the Vγ9Vδ2 T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisher, Jonathan P H, Flutter, Barry, Wesemann, Florian, Frosch, Jennifer, Rossig, Claudia, Gustafsson, Kenth, Anderson, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760299/ https://www.ncbi.nlm.nih.gov/pubmed/26942051 http://dx.doi.org/10.1080/2162402X.2015.1025194

Ejemplares similares

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO
por: Mueller, Ina, et al.
Publicado: (2017)

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
por: Terme, Mickaël, et al.
Publicado: (2014)

Correction: Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
Publicado: (2014)

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)
por: Arendt, A.-M., et al.
Publicado: (2023)

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells
por: Tivnan, Amanda, et al.
Publicado: (2017)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma
por: Golinelli, Giulia, et al.
Publicado: (2021)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting
por: Sabbih, Godfred O., et al.
Publicado: (2021)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

Digital TDPAC with rare earth isotope $^{169}$Yb, $^{147}$Gd, and $^{149}$Gd in Yb and Gd Doped CeO$_{2}$ and $^{147}$Gd in GdBa$_{2}$ Cu$_{3}$ O$_{7−\delta}$
por: Roeder, Jens, et al.
Publicado: (2011)

GD2 and GD3 synthase: novel drug targets for cancer therapy
por: Sphyris, Nathalie, et al.
Publicado: (2015)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

IMMU-02. CH14.18 IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: A META-ANALYSIS
por: Abdel-Khaleq, Sameerah, et al.
Publicado: (2021)

Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells
por: Yanagisawa, Makoto, et al.
Publicado: (2011)

GD2 expression in breast cancer
por: Orsi, Giulia, et al.
Publicado: (2017)

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
por: Erber, Ramona, et al.
Publicado: (2021)

Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma
por: Corrias, M V, et al.
Publicado: (2008)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
por: Blom, Thomas, et al.
Publicado: (2021)

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma
por: Schmitt, Julia, et al.
Publicado: (2022)

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
por: Siebert, Nikolai, et al.
Publicado: (2018)

Giant exchange coupling and field-induced slow relaxation of magnetization in Gd(2)@C(79)N with a single-electron Gd–Gd bond
por: Velkos, G., et al.
Publicado: (2018)

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer
por: Galan, Alba, et al.
Publicado: (2023)

Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma
por: Wellens, Lianne M., et al.
Publicado: (2020)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
por: van den Bijgaart, Renske J. E., et al.
Publicado: (2020)

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics
por: Zhang, Liyu, et al.
Publicado: (2021)

Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2022)

Functionalized GD2 Electrochemical Immunosensor to Diagnose Minimum Residual Disease of Bone Marrow in Neuroblastoma Effectively
por: Chen, Chong, et al.
Publicado: (2023)

Self-patterning Gd nano-fibers in Mg-Gd alloys
por: Li, Yangxin, et al.
Publicado: (2016)

GD2 oligosaccharide: target for cytotoxic T lymphocytes
Publicado: (1995)

K(3)Gd(PO(4))(2)
por: Zhao, Dan, et al.
Publicado: (2010)

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
por: Troschke-Meurer, Sascha, et al.
Publicado: (2019)

Upregulation of Ganglioside GD2 Synthase (GD2S), as a New Putative Cancer Stem Cell Marker in Breast Carcinomas
por: Mansoori, Maryam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b11lqb7kcetodes6a5g9t8al2o